HSK16149 capsule + Placebo

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Post-operative Pain

Conditions

Post-operative Pain

Trial Timeline

Mar 8, 2023 → Jul 5, 2023

NCT ID

NCT06007066

About HSK16149 capsule + Placebo

HSK16149 capsule + Placebo is a phase 2 stage product being developed by Haisco Pharmaceutical Group for Post-operative Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT06007066. Target conditions include Post-operative Pain.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06007066	Phase 2	Completed	Mar 8, 2023	Jul 5, 2023	Post-operative Pain

Competing Products

18 competing products in Post-operative Pain

See all competitors

Product	Company	Stage	Hype Score
Qutenza	Astellas Pharma	Pre-clinical	23
Test naproxen sodium tablet + Commercial naproxen sodium tablet + Commercial naproxen sodium liquid gels capsule + Placebo tablet	Johnson & Johnson	Phase 3	77
Test acetaminophen + Commercial acetaminophen + Commercial ibuprofen + Placebo	Johnson & Johnson	Phase 3	77
Paracetamol injection + Normal Saline injection + Morhpine PCA	Jiangsu Hengrui Medicine	Phase 2/3	65
AGN-151607 + Placebo	AbbVie	Phase 2	52
Comparator: MK0517 + Comparator: ondansetron	Merck	Phase 3	77
Sugammadex + Neostigmine + Atropine + Rocuronium + Fentanyl + Propofol + Sevoflurane	Merck	Approved	85
Aprepitant + Placebo to Aprepitant + Ondansetron + Placebo to match ondansetron	Merck	Phase 2	52
granisetron + granisetron	Roche	Approved	85
Parecoxib Sodium	Pfizer	Approved	84
lyrica	Pfizer	Phase 3	76
Placebo + Pregabalin + Pregabalin	Pfizer	Phase 1	32
Methylnaltrexone + Placebo	Pfizer	Phase 3	76
Ropivacaine	Lundbeck	Approved	82
Bupivacaine HCI without epinephrine + HTX-011	Heron Therapeutics	Phase 2	44
Sufentanil NanoTab PCA System/15 mcg + morphine IV PCA	Talphera	Phase 3	69
Sufentanil NanoTab PCA System/15 mcg + Placebo Sufentanil NanoTab PCA System	Talphera	Phase 3	69
Sufentanil Tablet 30 mcg + Placebo Tablet	Talphera	Phase 3	69

Other Products from Haisco Pharmaceutical Group

Crisugabalin + PlaceboApproved

Polyene phosphatidylcholine injection 930 mg QD + Magnesium Isoglycyrrhizinate injection 200 mg QDApproved

Cyclopofol + PropofolApproved

Ciprofol + PropofolApproved

CipepofolApproved